Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026)

Sol-Gel Technologies' (SLGL) quarterly Total Non-Current Liabilities came in at $831000.0 in Q1 2026, down 64.15% year-on-year from $2.3 million in Q1 2025, and down 11.12% on a QoQ basis from $935000.0 in Q4 2025.

Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has 11 years of Total Non-Current Liabilities data on file, last reported at $831000.0 in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 64.15% year-over-year to $831000.0 in Q1 2026; TTM through Mar 2026 was $831000.0, a 64.15% decrease from a year earlier, with the FY2025 full-year figure at $935000.0, down 45.35% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $831000.0, down from $935000.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for SLGL reached as high as $2.5 million in Q2 2025 and fell as low as $831000.0 in Q1 2026.
  • Historically, Total Non-Current Liabilities has averaged $1.7 million across 5 years, with a median of $1.7 million in 2022.
  • Across the five-year window, Total Non-Current Liabilities surged 95.3% in 2023 and sank 64.15% in 2026, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $1.1 million in 2022, then jumped by 95.3% to $2.1 million in 2023, then retreated by 19.33% to $1.7 million in 2024, then slumped by 45.35% to $935000.0 in 2025, then declined by 11.12% to $831000.0 in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $831000.0 in Q1 2026, $935000.0 in Q4 2025, and $2.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Sol-Gel Technologies 227.58 Mn 217.44 Mn - 831,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 831,000.00
Dec 31, 2025 935,000.00
Sep 30, 2025 2.42 Mn
Jun 30, 2025 2.47 Mn
Mar 31, 2025 2.32 Mn
Dec 31, 2024 1.71 Mn
Sep 30, 2024 1.74 Mn
Jun 30, 2024 1.90 Mn
Mar 31, 2024 2.04 Mn
Dec 31, 2023 2.12 Mn
Sep 30, 2023 2.23 Mn
Jun 30, 2023 1.14 Mn
Mar 31, 2023 1.06 Mn
Dec 31, 2022 1.09 Mn
Sep 30, 2022 1.22 Mn
Jun 30, 2022 1.41 Mn
Mar 31, 2022 1.72 Mn
Dec 31, 2021 1.90 Mn
Sep 30, 2021 1.86 Mn
Jun 30, 2021 2.00 Mn